Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Sygnis Pharma AG. (3/25/13). "Press Release: Sygnis Announces Management Board Changes (Ad hoc-Release)". Heidelberg & Madrid.

Organisations Organisation Sygnis Pharma AG
  Today Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Expedeon (Group)
  Organisation 2 Zeltia S.A.
  Today PharmaMar S.A. (MSE: PHM)
  Group PharmaMar (Group)
Product Product genomic technology
Persons Person Willinger, Peter (Apogenix 201506– CFO before Sygnis Pharma + Lion Bioscience)
  Person 2 de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
     


SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard), today announced that Chief Financial Officer (CFO) and member of the Management Board, Peter Willinger will be stepping down effective 31 March 2013 for personal reasons. He is leaving the company by mutual agreement with the Supervisory Board. Pilar de la Huerta, the company's CEO since 2012 and a former senior manager and CFO at Zeltia, S.A., the largest Spanish quoted biotech company, will now hold both positions, CFO and CEO.

**** end of ad hoc ****


For further information please contact:

SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta@sygnis.es


### Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of
future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to
publicly update or revise these statements in the light of new information or future results or for any other reason.

SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany, www.sygnis.de, Tel: +49-6221-454-6, Fax: +49-6221-454-700

   
Record changed: 2017-04-02

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for Expedeon (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top